The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).
Ignazio Ugo Carreca
No relevant relationships to disclose
Paolo D'alia
No relevant relationships to disclose
Giuseppe Bronte
No relevant relationships to disclose
Viviana Bazan
No relevant relationships to disclose
Dario Cova
No relevant relationships to disclose
Paolo Foa
No relevant relationships to disclose
Antonio Russo
No relevant relationships to disclose